Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB10.16 and Pembrolizumab in HPV16-positive Head and Neck Squamous Cell Carcinoma
NCT06016920Phase 2Recruiting
- Sponsor
- Nykode Therapeutics
- Start
- Dec 2023
- Primary completion
- Jan 2029
- Modality
- Prophylactic Vaccines, DNA Vaccines, Fc-Fusion Proteins
- Countries
- 7
01
Overview
A Phase 2 trial of VB10.16 in head and neck squamous cell carcinoma (HNSCC), sponsored by Nykode Therapeutics. Started Dec 2023; status: recruiting.
02
Drugs
VB10.16
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06016920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016920.